Diabetes is a condition where the body struggles to regulate blood sugar levels, often due to problems with insulin-producing cells in the pancreas. Scientists are working on ways to replace these damaged cells, and one promising approach involves growing new ones in the lab using human stem cells. These lab-grown clusters, called human islet-like organoids (HILOs), are designed to mimic the function of natural pancreatic islets.

However, a major challenge has been that these lab-grown cells often don’t work as well as the real thing. They may not respond properly to sugar in the blood or may produce insulin inconsistently. This study sheds light on why that happens—and how we might fix it.

This study describes a key role for a protein called FXYD2 in helping these lab-grown cells mature and function more like natural insulin-producing cells. In healthy human pancreatic cells, FXYD2 is present at high levels. But in the lab-grown versions, it’s often missing or reduced. The team found that when HILOs had higher levels of FXYD2, they were much better at sensing sugar and releasing insulin in response—just like real pancreatic cells.

The study shows that FXYD2 interacts with another protein called SRC, which helps send signals inside the cell. Together, they influence a pathway that controls which genes are turned on or off in the insulin-producing cells. This signaling pathway helps the cells develop the right features to do their job effectively. To test whether this discovery could make a real difference, the researchers transplanted HILOs with high levels of FXYD2 into diabetic mice. The results were striking: these mice had better blood sugar control compared to those that received cells with low FXYD2 levels.

This breakthrough suggests that FXYD2 could be used as a marker to identify the most functional lab-grown insulin-producing cells. It could also be a target for improving how these cells are made in the lab, bringing us closer to reliable, stem cell-based therapies for diabetes. In short, this study offers new hope for creating better, more effective treatments for people with diabetes—by helping lab-grown cells act more like the real thing.